Monalizumab clinical trials
Monalizumab is named as an intervention in 5 current clinical trials in our Italy, USA, France, Spain, Canada, South Korea, Belgium, Portugal, Taiwan, UK, Australia, Turkey, Germany, Poland, Brazil, Japan, Ireland, Netherlands, Switzerland, Austria and China registers. 2 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is AstraZeneca (3). The most-studied condition is Non-small Cell Lung Cancer.
How Monalizumab works
All drug targets →- NKG2-A/NKG2-B type II integral membrane protein inhibitor InhibitorTarget: KLRC1 killer cell lectin like receptor C1✓ In ChEMBL and the Guide to Pharmacology
- Head and neck squamous cell carcinomaPhase 3
- Non-small cell lung carcinomaPhase 3
- COVID-19Phase 2
- Acute myeloid leukemiaPhase 2
- Breast cancerPhase 2
- CancerPhase 2
- Colorectal cancerPhase 2
- Endometrial cancerPhase 2
- Gastric cancerPhase 2
- Myelodysplastic syndromePhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL4297787, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 8323, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Monalizumab
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Monalizumab
5 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Monalizumab
7 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| AstraZeneca | 3 |
| MedImmune LLC | 1 |
| Istituto Clinico Humanitas | 1 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Monalizumab trials
How many clinical trials are testing Monalizumab?
5 current trials in our Italy, USA, France, Spain, Canada, South Korea, Belgium, Portugal, Taiwan, UK, Australia, Turkey, Germany, Poland, Brazil, Japan, Ireland, Netherlands, Switzerland, Austria and China registers name Monalizumab (also registered as IPH2201) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Monalizumab trials recruiting patients?
Yes. 2 of the 5 trials are recruiting: 2 with sites in Italy, 1 with sites in USA, 1 with sites in France, 1 with sites in Spain, 1 with sites in Canada, 1 with sites in South Korea, 1 with sites in Belgium, 1 with sites in Portugal, 1 with sites in Taiwan, 1 with sites in Turkey and 1 with sites in Ireland. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Monalizumab clinical trials?
AstraZeneca (3), MedImmune LLC (1) and Istituto Clinico Humanitas (1). The number in brackets is how many trials each organisation leads.
Are there Monalizumab clinical trials in Ireland?
Yes. 1 trial in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Monalizumab works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Monalizumab works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Monalizumab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.